Core Insights - Jaypirca® (pirtobrutinib) has been approved in China for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least one line of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor [1][2] Company Overview - Innovent Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for various diseases, including oncologic and autoimmune conditions [2] - The company has launched 18 products and has 4 assets in Phase 3 or pivotal clinical trials, with 15 more molecules in early clinical stages [2] Product Details - Jaypirca is a highly selective, non-covalent (reversible) BTK inhibitor, which is 300 times more selective for BTK compared to 98% of other kinases tested in preclinical studies [2] - The approval in China is based on the Phase 3 BRUIN CLL321 study, which demonstrated that pirtobrutinib significantly prolonged median progression-free survival (PFS) to 14.0 months compared to 8.7 months for the investigator's choice regimen [1][2] Clinical Study Insights - The BRUIN CLL321 study enrolled 238 patients and compared pirtobrutinib monotherapy against IdelaR (idelalisib plus rituximab) or BR (bendamustine plus rituximab) [1] - The study showed a lower discontinuation rate due to treatment-related adverse events with pirtobrutinib (5.2% vs 21.1%) [1] Market Implications - The approval of pirtobrutinib represents a significant advancement for patients with relapsed or refractory CLL/SLL in China, addressing an urgent clinical need for new treatment options [1][2] - Innovent aims to leverage its brand presence and commercialization capabilities to enhance accessibility to this innovative therapy for cancer patients in need [1]
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma